Featured series 
Tag: Isaac Kohlberg
-
Nation & World
From the lab to COVID front lines
Aldatu Biosciences, a company born in Harvard’s labs and nurtured in its entrepreneurial ecosystem, helps the region ramp up COVID-19 testing.
-
Nation & World
Defending breakthrough research
Harvard initiates patent infringement suits to protect inventors’ rights in computer-chip technology.
-
Nation & World
Advancing ingenuity
Between academic discovery and product development lurks a lull in research funding that inventors call the “chasm of death,” where a prototype or a proof of concept can feel just…
-
Nation & World
Fueling the entrepreneurial spirit
A growing number of Harvard faculty members, fellows, and even students are looking to take their innovative ideas a step further and bring them to the marketplace.
-
Nation & World
Funding success, and finding it
Four years ago, Harvard’s Office of Technology Development launched its Accelerator Fund, a $10 million revolving account to be used as a bridge across the “valley” between creation and development. The fund is proving to be just such a bridge.
-
Nation & World
Guiding discoveries to the public
Harvard’s Office of Technology Development tries to ensure that the public sees the benefits of Harvard’s research by licensing new technology to companies.
-
Nation & World
Innovate, create
From oddities like breathable chocolate to history-making devices with profound societal effects, like the heart pacemaker, Harvard’s combination of questing minds, restless spirits, and intellectual seekers fosters creativity and innovation that’s finding an outlet in new inventions and companies.
-
Nation & World
Accelerator Fund boon to research
The Harvard Office of Technology Development’s Accelerator Fund helps researchers advance their work to the point where it’s attractive to private industry.
-
Nation & World
Harvard Medical School signs agreement with Merck to develop potential therapy for macular degeneration
Harvard Medical School announced May 23, 2006 that is has signed a multimillion-dollar license agreement with Merck & Co. Inc. to develop potential therapies for macular degeneration, an eye disease…